Navigation Links
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Date:8/6/2008

8. Estimates for the Distribution segment remain unchanged.

Research and development investment for 2008 is expected to be approximately $160 million. Selling, general and administrative expenses for 2008 are expected to be between $420 and $440 million. Amortization expense for 2008 is expected to be approximately $80 million.

Watson estimates adjusted earnings per diluted share will be between $1.90 and $2.00 and has increased its estimates for GAAP earnings per diluted share to between $1.90 and $2.00.

In 2008, the Company expects to incur pre-tax costs associated with the planned closure of its Carmel, NY manufacturing facilities of approximately $30 million which includes accelerated depreciation, severance, retention and other related plant closure costs. The Company also expects to incur $8.5 million of licensing costs. These and other charges are offset by the sales milestone from Barr Pharmaceuticals, the divestiture of the Company's interest in Somerset Pharmaceuticals, Inc. and the resolution of an Internal Revenue Service audit, and are excluded from Watson's 2008 adjusted earnings per diluted share forecast as detailed in Table 6 below.

Excluding special items as detailed in the EBITDA reconciliation Table 7 below, adjusted EBITDA is expected to be between $551 and $571 million.

Webcast and Conference Call Details

Watson will host a conference call and webcast today at 8:30 a.m. Eastern Daylight Time to discuss second quarter 2008 results, the outlook for 2008 and recent corporate developments. The dial-in number to access the call is (877) 251-7980, or from international locations, (706) 643-1573. A taped replay of the call will be available by calling (800) 642-1687 with access pass code 56190878. The replay may be accessed from international locations by dialing (706) 645-9291 and using the same pass code. This replay will remain in effect until midnight Eastern Daylight Time, August 15, 2008. To access the l
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related biology technology :

1. Watson to Present at the Bear Stearns 20th Annual Healthcare Conference
2. Watson Receives FDA Approval for Generic Accuneb(R)
3. Warner Chilcott and Watson Pharmaceuticals Announce Launch of Tilia(TM) Fe
4. Watson to Present at the 2008 Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Device Conference
5. Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results; Provides 2008 Outlook
6. Barr Subsidiary Sues Watson for SEASONIQUE(R) Patent Infringement
7. Watson Files FDA Application for Generic LYBREL(R)
8. FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceuticals TRELSTAR(R) DEPOT and TRELSTAR(R) LA
9. Cephalon Files Patent Infringement Lawsuit Against Watson Pharmaceuticals
10. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
11. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/20/2015)... , April 20, 2015   Meditope Biosciences, ... using its proprietary technology, today announced presentation of data ... the development of antibody-drug conjugates (ADCs). The data were presented ... taking place April 18-22 in Philadelphia ... these data which point to the many commercial applications ...
(Date:4/20/2015)... 2015 Whitehouse Laboratories is pleased and ... most recent Food and Drug Administration (FDA) inspection and ... five day, GMP compliance inspection, as based upon 21CFR ... through April 6th and was granted NAI (no action ... the strict Good Manufacturing Practice (GMP) quality system required ...
(Date:4/17/2015)... ALTO, Calif. , April 17, 2015 ... has received a SBIR grant from the ... the National Institutes of Health (NIH). The ... research efforts in the development of breakthrough ... genomes using specially fabricated substrates. Centrillion has ...
(Date:4/17/2015)... (PRWEB) April 17, 2015 CIO Review ... for its 20 Most Promising Pharma and Life Science ... MMIS’s MediSpend global compliance software platform for life sciences ... selected by a panel of experts and members of ... entrepreneurship. “MMIS’s MediSpend Platform has been on our radar ...
Breaking Biology Technology:Meditope Biosciences Presents Data At The American Association Of Cancer Research (AACR) Annual Meeting Validating Its SnAP Technology Platform 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 2Whitehouse Laboratories Completes FDA Inspection with No Form 483 – No Observations 3MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2
... human patients into fruit flies, we,ve created the first ... says Albena Jordanova. "Now we have the opportunity to ... to start looking for substances with therapeutic value." ... VIB researchers working at the University of Antwerp and ...
... Corporation,s (OTC Bulletin Board: ETCC) ("ETC" or the "Company") ... Health, Labor and Welfare (MHLW) has given accreditation to ... , ETC worked closely with our Japanese distributor (Koike ... hyperbaric chambers passed every certification requirement. Obtaining the accreditation ...
... France and RICHMOND, Calif., June 22 ... Lumiphore Inc., a biotechnology leader in new proprietary ... announced that they have signed an agreement on ... tests. , , Under the agreement, ...
Cached Biology Technology:Fruit fly steps in to fight human disease 2Environmental Tectonics Corporation's BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 2Environmental Tectonics Corporation's BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 3Environmental Tectonics Corporation's BioMedical Division Achieves Foreign Manufacturer Accreditation in Japan 4BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 2BRAHMS, Cezanne and Lumiphore Announce Partnership for Diagnostic Tests 3
(Date:4/9/2015)... 9, 2015 Synaptics Inc. (NASDAQ: SYNA ), ... that it will report financial results for the third ... after the close of market. The company will host ... 2:00 p.m. PT (5:00 p.m. ET), during which management ... on the live call, analysts and investors should dial ...
(Date:4/2/2015)... April 2, 2015 At its 2015 ACMG ... City , the American College of Medical Genetics ... directors to its Board.  Members of the ACMG Board ... for forming and advancing its policies and programs. ACMG ... "It,s an eventful time in medical genetics ...
(Date:4/1/2015)... BOSTON , April 1, 2015   Medisafe ... 1.5 million users across iOS and ... has begun integrating biofeedback into the platform to allow ... health outcomes. For the first time, patients will be ... missing a dose impacts important biometrics, such as glucose ...
Breaking Biology News(10 mins):Synaptics to Report Third Quarter Results on April 23 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Medisafe Announces Launch of Biometric Integration, Enabling Patients to Stay Adherent to Their Meds and See Tangible Health Results 2
... of Adelaide are a promising step forward in helping ... babies, by reducing the likelihood of adverse inflammatory responses to ... medical procedures experienced by preterm babies, who are often anemic ... Adelaide,s Robinson Institute studied 28 preterm babies (at ...
... is a serious complication of pregnancy and the major cause ... the U.S. It affects about one in 20 pregnancies. The ... urine. The cause of preeclampsia is still unclear. Dr. Florian ... Delbrck Center (MDC) and the Charit), Dr. Ralf Dechend (ECRC ...
... causes of dementia. In Germany and Switzerland alone, around ... doubling of the number of patients worldwide within the ... including amyloid- (Aβ) among others, in patients, brains plays ... from the Department of Neuropathology at Charit and his ...
Cached Biology News:Better blood transfusions for preterm babies 2New risk factor identified for high blood pressure during pregnancy 2New risk factor identified for high blood pressure during pregnancy 3New risk factor identified for high blood pressure during pregnancy 4Alzheimer's disease in mice alleviated promising therapeutic approach for humans 2
Preparation Note: Prepared by method of Wimmer, E., et al., Biochemistry, 7, 2623 (1968). Quality Clarifier: Acceptor Activity: approx. 1000 picomoles phenylalanine per A 260 unit (not determined b...
A collection of 42 spots with normal tissues from different organs of C57 mice, rat and human....
... which is based on a new flow-through technology, ... in situ hybridization of tissues on microscope slide ... study of gene expression, in situ hybridization (ISH) ... can be used to validate and confirm results ...
... voice-coil scanning and positioning system is ... have to be positioned or scanned ... It provides superior responsiveness compared to ... mechanics (X or XY stage) are ...
Biology Products: